

PI	DEPARTMENT	FUNDING AGENCY	FLOW THRU AGENCY	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
PETERSEN B E	PATHOLOGY & LABORATORY MED	AM CANCER SOCIETY		FLATOXIN B1 CARCINOGENESIS IN RAT LIVER STEM CELLS	07/01/2005	06/30/2008	\$138,000.00	05/31/2005
SAYESKI P P	PHYSIOLOGY	AM HEART ASSOCIATION		MECHANISMS OF JAK2 TYROSINE ACTIVATION AND PHARMACOLOGICAL INHIBITION	07/01/2005	06/30/2007	\$60,000.00	05/25/2005
SUMNERS C	MEDICINE	AM HEART ASSOCIATION - FL		HEALTH SCIENCE STUDENT SUMMER RESEARCH	07/01/2005	06/30/2007	\$10,800.00	05/19/2005
SAYESKI P P	PHYSIOLOGY	AM HEART ASSOCIATION - FL		THE ROLE OF JAK2 IN MEDIATING ANGIOTENSIN II-MEDIATED IP3 RECEPTOR DEGRADATION	07/01/2005	06/30/2006	\$21,000.00	05/20/2005
SUMNERS C	PHYSIOLOGY	AM HEART ASSOCIATION - FL		MACROPHAGE MIGRATION INHIBITORY FACTOR: EXPRESSION IN HYPERTENSIVE RAT NEURONS	07/01/2005	06/30/2007	\$21,000.00	05/31/2005
SU Y	MEDICINE	AM HEART ASSOCIATION - FL		HYPEROXIC REGULATION OF ENO ^W IN LUNG ENDOTHELIUM: ROLE OF ENOS-ACTING INTERACTION	07/01/2005	06/30/2007	\$60,000.00	05/24/2005
GUMS J G	COMMUNITY HEALTH & FAMILY MED	AM HOME PRODUCTS CORP		STATISTICAL MODELS TO PROJECT FUTURE IMPACT FROM RESISTANCE PATTERNS IN A HOSPITAL SETTING	10/22/2004	06/30/2006	\$5,000.00	05/20/2005
VEGA K J	UFHSCJ/MEDICINE	ASTRAZENECA		A MULTICENTER, DOUBLE-BLIND, RANDOMIZED TRIAL INTRAGASTRIC ACID CONTROL & HEALING EFFECTS OF ESOMEPRAZOLE	10/11/2004	10/19/2005	\$6,500.00	05/17/2005

PI	DEPARTMENT	FUNDING AGENCY	FLOW THRU AGENCY	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
MOZINGO D W	MEDICINE	BAXTER HEALTHCARE CORP		A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FIBRIN SEALANT WITH 4IU/ML	01/12/2005	01/20/2006	\$6,150.00	05/17/2005
PIGOTT T A	PSYCHIATRY	BRISTOL-MYERS SQUIBB COMPANY		ARIPIPRAZOLE IN THE TREATMENT OF PATIENTS WITH BIPOLAR I DISORDER WITH A MAJOR DEPRESSIVE EPISODE	06/25/2004	06/24/2006	\$4,223.00	05/06/2005
CONTI J B	MEDICINE	CORDIS CORP		CORDIS FELLOWSHIP GRANT	04/07/2005	04/06/2006	\$60,000.00	05/02/2005
SPENCER JR L T	PEDIATRICS	CORUS PHARMA		EVALUATION OF CF PATIENT PERCEPTION OF SYMPTOM IMPROVEMENT FOLLOWING INHALED ANTIBIOTIC TREATMENT:	03/18/2005	02/06/2006	\$2,851.73	05/03/2005
YANG T P	BIOCHEMISTRY & MOLECULAR BIO	CTRS FOR DISEASE CONTROL		IPA AGREEMENT BETWEEN UF AND THE DIVISION OF BIRTH DEFECTS & DEVELOPMENTAL DISABILITIES	12/01/2004	09/30/2005	\$6,786.75	05/05/2005
FLOTTE T R	PEDIATRICS	CYSTIC FIBROSIS FOUNDATION		THE ORIGINS OF CYSTIC FIBROSIS RELATED DIABETES	07/01/2005	06/30/2006	\$27,854.00	05/31/2005
SIDDIQUI T	CANCER CENTER	EASTERN COOP ONCOLOGY GROUP	SUB w/ NIH	NSABP B-35 A CLINICAL TRAIN COMPARING ANASTROZOLE WITH TAMOXIFEN IN POSTMENOPAUSAL PATIENTS WITH DUCTAL	05/13/2005	05/12/2006	\$2,300.00	05/13/2005
JAMIESON K	MEDICINE	EASTERN COOP ONCOLOGY GROUP		E3999 A RANDOMIZED, PLACEBO-CONTROLLED DOUBLE BLIND TRIAL OF THE ADMINISTRATION.....	05/04/2005	03/16/2006	\$8,850.00	05/06/2005

PI	DEPARTMENT	FUNDING AGENCY	FLOW THRU AGENCY	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
SOUTHWICK F S	MEDICINE	EMORY UNIVERSITY	SUB w/ CDC	ANTHRAX LETHAL & EDEMA TOXIN PARALYZE PHAGOCYTE HOST DEFENSE S BY ALTERING NEUTROPHIL AND MACROPHAGE	03/01/2004	02/28/2005	\$50,000.00	05/02/2005
NGUYEN M T	MEDICINE	ENZON INC		CLEAR II COLLABORATIVE EXCHANGE OF ANTIFUGAL RESEARCH	09/10/2004	09/10/2005	\$45,000.00	05/31/2005
HUANG S	PEDIATRICS	GENENTECH INC		ANEPIDEMIOLOGIC STUDY OF XOLAIR (OMALIZUMAB), EVALUATION CLINICAL EFFECTIVENESS AND LONG TERM	08/23/2004	06/01/2011	\$565.00	05/25/2005
MEADER S R	RADIOLOGY	GENERAL ELECTRIC COMPANY		...STUDY TO ASSESS THE EFF & SAF OF 0.1 MMOL/KG OMNISSCAN (GADODIAMIDE INJ) FOR MRA OF THE AORTO-ILIAC ARTERIES	02/01/2005	11/30/2005	\$12,262.50	05/19/2005
TYNER M	CTR CLINICAL TRIALS RES (CCTR)	GLAXO SMITHKLINE		A SINGL-MASKED, RANDOMIZED (WITH RESPECT TO PLACEBO) PLACEBO CONTROLLED, PARALLEL-GROUP, DOSE-RISING	01/26/2005	01/21/2006	\$330,855.00	05/04/2005
BURKART T A	MEDICINE	INST FOR CLINICAL RESEARCH	SUB w/ US DOD	EFFICACY OF ICD THERAPY IN PATIENTS WITH VT/VF WITH MILDLY DEPRESSED LEFT VENTRICULAR (AVID 2 TRIAL)	02/01/2004	02/01/2009	\$2,500.00	05/12/2005
LONDON W B	STATISTICS	NATL CHILDHOOD CANCER FDTN	SUB w/ NIH	COG CCOP	06/01/2004	05/31/2005	\$28,743.00	05/17/2005
COGLE C R	MEDICINE	NATL INSTITUTES OF HEALTH		DEFINING THE HUMAN HEMANGIOBLAST	06/01/2005	05/31/2010	\$123,390.00	05/26/2005

PI	DEPARTMENT	FUNDING AGENCY	FLOW THRU AGENCY	PROJECT TITLE	PROJECT BEGIN DATE	PROJECT END DATE	AMOUNT AWARDED	AWARD DATE
KOENIG J M	PEDIATRICS	NATL INSTITUTES OF HEALTH		NEUTROPHIL APOPTOSIS AND NEONATAL INFLAMMATION	05/01/2005	03/31/2010	\$239,735.00	05/31/2005
WANG K W	PSYCHIATRY	NATL INSTITUTES OF HEALTH		BIOCHEMICAL BASIS OF AXONAL & MYELIN INJURY IN HEAD TRAUMA	05/01/2005	04/30/2009	\$479,318.00	05/11/2005
LAW B K	PHARMACOLOGY & THERAPEUTICS	OAK RIDGE ASSOC UNIVERSITIES		RALPH E POWE JUNIOR FACULTY ENHANCEMENT AWARD	04/21/2005	04/20/2006	\$5,000.00	05/06/2005
MOREB J S	CANCER CENTER	OSIRIS THERAPEUTICS INC		OTI-010 PROTOCOL #240: A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO	03/01/2003	12/31/2004	\$5,250.00	05/04/2005
SAMRAJ G P	COMMUNITY HEALTH & FAMILY MED	SANOFI-SYNTHELABO RESEARCH US		PROSPECTIVE, OBSERVATIONAL REGISTRY AND PATIENT SURVEY OF THE MANAGEMENT OF MENC SYMPTOMATIC BENIGN	02/07/2005	08/05/2005	\$250.00	05/19/2005
EJAZ A A	MEDICINE	SCIOS NOVA INC		PROPHYLACTIC USE OF NESIRITIDE (BRAIN NATRIURETIC PEPTIDE, B NP) FOR THE PREVENTION OF ACUTE RENAL	12/13/2004	02/02/2006	\$133,895.20	05/25/2005
KEM W R	PHARMACOLOGY & THERAPEUTICS	UNIV OF COLORADO	SUB w/ NIH	MOLECULAR NEUROBIOLOGY OF SCHIZOPHRENIA	04/01/2005	06/30/2005	\$37,000.00	05/10/2005
KEM W R	PHARMACOLOGY & THERAPEUTICS	UNIV OF COLORADO	SUB w/ NIH	MOLECULAR NEUROBIOLOGY OF SCHIZOPHRENIA	04/01/2005	06/30/2005	\$63,000.00	05/10/2005